Basem William, MD
Hematology & Oncology · Marion, OHNPI 1952416505
Payments from drug & device makers
Across 236 payments — averaging $3165.76 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Gilead$292K
- AbbVie$141K
- Otsuka Pharmaceutical Co., Ltd.$138K
- Karyopharm Therapeutics Inc.$49K
- Beone Medicines Ltd.$34K
- ADC Therapeutics America, Inc.$23K
- plus $71K from 26 others
Across 1 payment — averaging $108.81 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Gilead$109
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Gilead | 37 | $291,645 |
| AbbVie | 19 | $140,894 |
| Otsuka Pharmaceutical Co., Ltd. | 8 | $137,547 |
| Karyopharm Therapeutics Inc. | 61 | $49,175 |
| Beone Medicines Ltd. | 1 | $33,536 |
| ADC Therapeutics America, Inc. | 4 | $23,200 |
| Innate Pharma, Inc | 4 | $16,267 |
| Morphosys AG | 1 | $12,000 |
| Incyte Corporation | 15 | $8,016 |
| Kyowa Kirin, Inc. | 7 | $7,794 |
| Kyowa Kirin Pharmaceutical Development, Inc | 2 | $4,750 |
| Bristol Myers Squibb | 7 | $4,294 |
| E.r. Squibb & Sons, L.L.C. | 2 | $3,806 |
| AstraZeneca(2 entities) | 5 | $3,069 |
| Genmab U.S., Inc. | 11 | $2,908 |
| Adaptive Biotechnologies Corporation | 20 | $2,247 |
| Morphosys, US Inc. | 2 | $1,935 |
| Seagen Inc. | 3 | $1,464 |
| Pfizer | 2 | $1,124 |
| Novartis | 6 | $479 |
| National Marrow Donor Program | 2 | $317 |
| Syndax Pharmaceuticals, Inc. | 2 | $148 |
| Sanofi-aventis U.S. LLC | 1 | $120 |
| Dova Pharmaceuticals | 1 | $95 |
| Alnylam Pharmaceuticals Inc. | 3 | $60 |
| Amgen | 3 | $51 |
| Jazz Pharmaceuticals Inc. | 2 | $48 |
| Daiichi Sankyo Inc. | 1 | $43 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $30 |
| Apellis Pharmaceuticals, Inc. | 1 | $23 |
| Astellas Pharma US Inc | 1 | $18 |
| CTI Biopharma Corp. | 1 | $16 |
How this compares
$747,119 in reported general payments places this provider in the 85th percentile of 450 hematology & oncology providers in Ohio.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Other hematology & oncology in Marion
- Yanis BoumberMarion$1.6M
- Afshin DowlatiCleveland$25.1M
- Brian HillCleveland$11.6M
- Trisha Wise-DraperCincinnati$9.8M
- Davendra SohalCincinnati$8.6M
- Christopher HoimesCleveland$7.5M
- Balazs HalmosCleveland$7M
- David WaterhouseCincinnati$5.7M
- Dale ShepardCleveland$5.1M
- Paolo CaimiCleveland$4.2M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.